These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31281311)

  • 1. Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus Monkeys.
    Theil D; Smith P; Huck C; Gilbart Y; Kakarieka A; Leppert D; Rauld C; Schmid C; Baumgartner R; Stuber N; Cordoba F; Dubost V; Darribat K; Jivkov M; Frieauff W; Kneuer R; Stoeckli M; Reinker S; Mansfield K; Carballido JM; Couttet P; Weckbecker G
    Front Immunol; 2019; 10():1340. PubMed ID: 31281311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-Dose Subcutaneous Anti-CD20 Treatment Depletes Disease Relevant B Cell Subsets and Attenuates Neuroinflammation.
    Huck C; Leppert D; Wegert V; Schmid C; Dunn R; Weckbecker G; Smith PA
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):709-719. PubMed ID: 31435856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys.
    Schröder C; Azimzadeh AM; Wu G; Price JO; Atkinson JB; Pierson RN
    Transpl Immunol; 2003; 12(1):19-28. PubMed ID: 14551029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution and efficacy of ofatumumab and ocrelizumab in humanized CD20 mice following subcutaneous or intravenous administration.
    Torres JB; Roodselaar J; Sealey M; Ziehn M; Bigaud M; Kneuer R; Leppert D; Weckbecker G; Cornelissen B; Anthony DC
    Front Immunol; 2022; 13():814064. PubMed ID: 35967378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous versus intravenous administration of rituximab: pharmacokinetics, CD20 target coverage and B-cell depletion in cynomolgus monkeys.
    Mao CP; Brovarney MR; Dabbagh K; Birnböck HF; Richter WF; Del Nagro CJ
    PLoS One; 2013; 8(11):e80533. PubMed ID: 24265828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.
    Vugmeyster Y; Beyer J; Howell K; Combs D; Fielder P; Yang J; Qureshi F; Sandlund B; Kawaguchi L; Dummer W; Lowman H; McKeever K
    J Immunother; 2005; 28(3):212-9. PubMed ID: 15838377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell subsets in blood and lymphoid organs in Macaca fascicularis.
    Vugmeyster Y; Howell K; Bakshi A; Flores C; Hwang O; McKeever K
    Cytometry A; 2004 Sep; 61(1):69-75. PubMed ID: 15351991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys.
    Bellot M; Luetjens CM; Bagger M; Horvath C; Sutter E; DeLise A; Brees D; Carballido JM; Pingili R; Ramanathan K; Kieseier BC; Hellwig K
    Reprod Toxicol; 2022 Mar; 108():28-34. PubMed ID: 34942355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ofatumumab Modulates Inflammatory T Cell Responses and Migratory Potential in Patients With Multiple Sclerosis.
    von Essen MR; Hansen RH; Højgaard C; Ammitzbøll C; Wiendl H; Sellebjerg F
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35672145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of specific anti-B and/or anti-plasma cell immunotherapy on antibody production in baboons: depletion of CD20- and CD22-positive B cells does not result in significantly decreased production of anti-alphaGal antibody.
    Alwayn IP; Xu Y; Basker M; Wu C; Buhler L; Lambrigts D; Treter S; Harper D; Kitamura H; Vitetta ES; Abraham S; Awwad M; White-Scharf ME; Sachs DH; Thall A; Cooper DK
    Xenotransplantation; 2001 Aug; 8(3):157-71. PubMed ID: 11472623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
    Hauser SL; Kappos L; Bar-Or A; Wiendl H; Paling D; Williams M; Gold R; Chan A; Milo R; Das Gupta A; Karlsson G; Sullivan R; Graham G; Merschhemke M; Häring DA; Vermersch P
    Neurol Ther; 2023 Oct; 12(5):1491-1515. PubMed ID: 37450172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of anti-CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix.
    Vugmeyster Y; Howell K; Bakshl A; Flores C; Canova-Davis E
    Cytometry A; 2003 Apr; 52(2):101-9. PubMed ID: 12655653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-transplant repopulation of naïve and memory T cells in blood and lymphoid tissue after alemtuzumab-mediated depletion in heart-transplanted cynomolgus monkeys.
    Marco MR; Dons EM; van der Windt DJ; Bhama JK; Lu LT; Zahorchak AF; Lakkis FG; Cooper DK; Ezzelarab MB; Thomson AW
    Transpl Immunol; 2013 Dec; 29(1-4):88-98. PubMed ID: 24120957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel humanized anti-CD20 antibody BM-ca binds to a unique epitope and exerts stronger cellular activity than others.
    Kobayashi H; Matsunaga Y; Uchiyama Y; Nagura K; Komatsu Y
    Cancer Med; 2013 Apr; 2(2):130-43. PubMed ID: 23634281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CyTOF-Enabled Analysis Identifies Class-Switched B Cells as the Main Lymphocyte Subset Associated With Disease Relapse in Children With Idiopathic Nephrotic Syndrome.
    Fribourg M; Cioni M; Ghiggeri G; Cantarelli C; Leventhal JS; Budge K; Bin S; Riella LV; Colucci M; Vivarelli M; Angeletti A; Perin L; Cravedi P
    Front Immunol; 2021; 12():726428. PubMed ID: 34621271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys.
    Vugmeyster Y; Howell K; McKeever K; Combs D; Canova-Davis E
    Int Immunopharmacol; 2003 Oct; 3(10-11):1477-81. PubMed ID: 12946444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fully human anti-BAFF inhibitory monoclonal antibody tabalumab does not adversely affect T-dependent antibody responses in cynomolgus monkey (Macaca fasicularis): A summary of three pre-clinical immunotoxicology evaluations.
    Komocsar WJ; Blackbourne JL; Halstead CA; Winstead CJ; Wierda D
    J Immunotoxicol; 2016; 13(1):7-19. PubMed ID: 25585959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys.
    Nickerson-Nutter C; Tchistiakova L; Seth NP; Kasaian M; Sibley B; Olland S; Zollner R; Brady WA; Mohler KM; Baum P; Wahl A; Herber D; Vugmeyster Y; Wensel D; Wolfman NM; Gill D; Collins M; Dunussi-Joannopoulos K
    Rheumatology (Oxford); 2011 Jun; 50(6):1033-44. PubMed ID: 21258049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [B-cell depletion in the therapy of multiple sclerosis: ofatumumab is a new player].
    Pukoli D; Vécsei L
    Ideggyogy Sz; 2022 May; 75(5-06):163-169. PubMed ID: 35819344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study.
    Bar-Or A; Wiendl H; Montalban X; Alvarez E; Davydovskaya M; Delgado SR; Evdoshenko EP; Giedraitiene N; Gross-Paju K; Haldre S; Herrman CE; Izquierdo G; Karelis G; Leutmezer F; Mares M; Meca-Lallana JE; Mickeviciene D; Nicholas J; Robertson DS; Sazonov DV; Sharlin K; Sundaram B; Totolyan N; Vachova M; Valis M; Bagger M; Häring DA; Ludwig I; Willi R; Zalesak M; Su W; Merschhemke M; Fox EJ
    Mult Scler; 2022 May; 28(6):910-924. PubMed ID: 34605319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.